Strategic CDMO Intravacc positions itself as an established independent CDMO bridging discovery to phase I/II trials in infectious disease and therapeutic vaccines, presenting a clear selling point for partnerships seeking late-stage translational support and scalable manufacturing capabilities.

Funding Validation CARB-X funding and publicized grant support for gonorrhea vaccine programs indicate validated demand for preventive vaccines and non-dilutive funding credibility, creating opportunities to approach customers with co-development or funded collaboration angles.

Recent Partnerships Recent collaborations with SynphaBase and Primrose Bio demonstrate Intravacc’s active ecosystem engagement and capacity to integrate specialized glycochemistry and conjugate vaccine manufacturing, suggesting cross-selling opportunities with biotech firms pursuing advanced vaccine tech.

Global Reach Despite a small employee base, the company’s positioning within Utrecht Science Park Bilthoven and its global tech stack (AWS, Google Cloud, SAP, Shopify, WordPress) signals readiness for scalable digital processes and international projects, appealing to customers seeking reliable CDMO partners with modern infrastructure.

Growth Potential With reported revenue in the low millions and strategic funding, there is room to expand service offerings and capacity for infectious disease and biologics programs, providing sales opportunities around extended development services, late-stage manufacturing, and supply chain readiness.